Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Non-Genotype 1 HCV Infection

NCT02378961 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

128

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C Virus Infection

Interventions

DRUG: VOX
DRUG: SOF/VEL

Sponsor

Gilead Sciences